Supporting robust Real-World Evidence for HTA/ Payer decision-making

RWE4Decisions is a multi-stakeholder Learning Network on how fit-for-purpose RWE over the life cycle of highly innovative medicines can inform HTA/Payer decisions.

RWE4Decisions Webinar: Clinical Teams’ Role in Real-World Data Generation for Healthcare Payers’ Decision-Making

RWE4Decisions Webinar: How Can Horizon Scanning Support Early Dialogues and RWE Generation?

2026 RWE4Decisions Symposium: 𝙊𝙥𝙩𝙞𝙢𝙞𝙨𝙞𝙣𝙜 𝙍𝙒𝙀 𝙩𝙤 𝘿𝙚𝙡𝙞𝙫𝙚𝙧 𝙑𝙖𝙡𝙪𝙚 𝙞𝙣 𝙃𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚

RWE4Decisions Webinar: Improving Rare Disease Data Availability and Quality for HTA/Payers

Our work is led by a dedicated Steering Group of experts, and brings together HTA bodies, payers, policymakers, regulatory agencies, clinicians, patient groups, researchers, registry-holders, data analysts, industry and academia for open dialogue about key RWE issues for HTA/Payers.

Jo De Cock

Senior Adviser

INAMI-RIZIV

Niklas Hedberg

Chief Pharmacist

Swedish Dental and Pharmaceuticals Benefits Agency (TLV)

Piia Rannanheimo

Chief Specialist

Fimea

Cláudia Furtado

Head of Health Technology Assessment

INFARMED

Christian Dehlendorff

Biostatistical Chief Consultant

Danish Medicines Council

Shaun Rowark

Associate Healthcare Director Data Analytics

NICE

Hans-Georg Eichler

Consultant Physician

Association of Austrian Social Insurance Institutions

Matti Aapro

Director

Genolier Cancer Centre

Dr Sami Pakarinen

Chief Medical Officer of Clinical Auditing and Cardiologist

Helsinki University Hospital

François Houÿez

Treatment Information and Access Director and Health Policy Advisor

EURORDIS-Rare Diseases Europe

Chris Sotirelis

Patient Advocate for the Thalassaemia Community

Steven Hartjes

Chaiman of the ICT working group

Hematon

Eric Sutherland

Senior Health Economist

Organisation for Economic Co-operation and Development

Seamus Kent

Assistant Professor, Erasmus School of Health Policy & Management (ESHPM)

Erasmus University Rotterdam

Victoria Hodgkinson

Executive Director, Digital Health Program

University of Calgary, Canada

Ashley Jaksa

Principal, Research Partnerships

Pedestal Health

Alexander Natz

Secretary General

EUCOPE

Antonia Morga

Executive Director & Head, New Product Planning, Global Value Evidence

Astellas

Bengt Liljas

Group Director Health Economics & Payer Evidence, OMAP

AstraZeneca

Claire Martin

Global Policy Lead, RWE Centre of Excellence, Medical & Evidence

Bayer

Lara Wolfson

Associate Vice President & Head HTA Statistics

MSD

Ansgar Hebborn

Head of European Access Policy Affairs

Hoffmann-La Roche AG

Andre Vidal Pinheiro

Vice-President – Head of Patient Value & Access EUCAN, Global Pricing & Access

Takeda

Adam Parnaby

Lead, Global Policy & Access

Brystol Myers Squibb

Diana Sinkevich

Vice President of Market Access EU & International and Global HEOR

Chiesi

Karen Facey

Senior Adviser HTA

FIPRA

François Meyer

Special Advisor HTA,

FIPRA

SPOTLIGHT

Latest Resources

Explore our latest resources designed to support real-world evidence planning and evaluation:

September 15, 2026

Report

Roundtable Report: Can Real-World Data Explain Patient Benefit? (3 June 2026)

August 24, 2026

Report

Roundtable Report: Real-World Evidence for HTA Decision-Making in Oncology (18 September 2025)

April 13, 2026

Report

Roundtable Report: Planning Real-World Data Collection to Demonstrate Real-Life Effectiveness: Alzheimer’s Disease (18 February 2026)

March 24, 2025

Report

Roundtable Report: WHO Novel Medicines Platform draft guide principles for Managed Entry Agreement (20 February 2025)

August 3, 2026

Paper

Demonstrating Transportability of Real-World Evidence: What Do HTA Bodies and Health Technology Developers Need?

June 17, 2025

Paper

Actions for Stakeholders to Develop Better Real-World Evidence for HTA/Payer Decision-Making

February 17, 2025

Planning Post-Launch Evidence Generation: Lessons from France, England, and Spain

November 2, 2022

Paper

Can we use existing guidance to support the development of robust real-world evidence for HTA/Payer decision-making?

May 7, 2026

Consultation response

RWE4Decisions’ response to the European Commission’s call for feedback on the EHDS Draft Implementing Act on dataset descriptions for the secondary use of electronic health data

December 3, 2025

RWE4Decisions response to the TEHDAS2 public consultation on guidelines for the European Health Data Space Regulation implementation

August 27, 2025

Call to action

RWE4Decisions calls for a Multi-Stakeholder EU Learning Network on RWE within the European Health Data Space

March 5, 2025

Policy brief

RWE4Decisions Contribution to a Call for Effective Stakeholder Engagement and Capacity Building during the Implementation of the EHDS (5 March 2025)

September 15, 2026

Report

Can Real-World Data Explain Patient Benefit? (3 June 2026)

June 10, 2026

Report

Mobilising Real-World Data to Enhance HTA/Payer Decision-Making | RWE4Decisions Symposium Report (20 November 2025)

February 3, 2026

Report

Transforming Real-World Evidence with AI: From Data to Decisions (15 October 2025)

June 6, 2025

Report

2024 Symposium Report: Developing RWE to Deliver Innovation in HTA